JOP20240257A1 - مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتها - Google Patents
مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتهاInfo
- Publication number
- JOP20240257A1 JOP20240257A1 JOJO/P/2024/0257A JOP20240257A JOP20240257A1 JO P20240257 A1 JOP20240257 A1 JO P20240257A1 JO P20240257 A JOP20240257 A JO P20240257A JO P20240257 A1 JOP20240257 A1 JO P20240257A1
- Authority
- JO
- Jordan
- Prior art keywords
- oxoindolinylamide
- derivatives
- methods
- compounds
- nlrp3 inhibition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341614P | 2022-05-13 | 2022-05-13 | |
| PCT/US2023/066934 WO2023220715A1 (en) | 2022-05-13 | 2023-05-12 | Oxoindolinyl amide derivatives for inhibiting nlrp3 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240257A1 true JOP20240257A1 (ar) | 2024-11-12 |
Family
ID=86760226
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0257A JOP20240257A1 (ar) | 2022-05-13 | 2024-11-12 | مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتها |
| JOJO/P/2024/0258A JOP20240258A1 (ar) | 2022-05-13 | 2024-11-12 | مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتها |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0258A JOP20240258A1 (ar) | 2022-05-13 | 2024-11-12 | مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتها |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240368131A1 (enExample) |
| EP (1) | EP4522591A1 (enExample) |
| JP (1) | JP2025516719A (enExample) |
| KR (1) | KR20240172228A (enExample) |
| CN (1) | CN119212978A (enExample) |
| AU (1) | AU2023268557A1 (enExample) |
| CA (1) | CA3251062A1 (enExample) |
| CL (1) | CL2024003460A1 (enExample) |
| CO (1) | CO2024015371A2 (enExample) |
| IL (1) | IL316674A (enExample) |
| JO (2) | JOP20240257A1 (enExample) |
| MX (1) | MX2024013978A (enExample) |
| PE (1) | PE20251252A1 (enExample) |
| TW (1) | TW202409013A (enExample) |
| WO (1) | WO2023220715A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026510921A (ja) * | 2023-03-17 | 2026-04-10 | ヴェンタス・セラピューティクス・ユー・エス・インコーポレイテッド | Ｎｌｒｐ３を阻害するためのアミド誘導体及びその使用 |
| WO2025106863A1 (en) * | 2023-11-15 | 2025-05-22 | Ventus Therapeutics U.S., Inc. | Lactam derivatives for inhibiting nlrp3 and uses thereof |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| UY38687A (es) * | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
-
2023
- 2023-05-12 WO PCT/US2023/066934 patent/WO2023220715A1/en not_active Ceased
- 2023-05-12 AU AU2023268557A patent/AU2023268557A1/en active Pending
- 2023-05-12 PE PE2024002511A patent/PE20251252A1/es unknown
- 2023-05-12 EP EP23730335.9A patent/EP4522591A1/en active Pending
- 2023-05-12 CN CN202380040044.4A patent/CN119212978A/zh active Pending
- 2023-05-12 IL IL316674A patent/IL316674A/en unknown
- 2023-05-12 JP JP2024567587A patent/JP2025516719A/ja active Pending
- 2023-05-12 CA CA3251062A patent/CA3251062A1/en active Pending
- 2023-05-12 KR KR1020247038886A patent/KR20240172228A/ko active Pending
- 2023-05-12 TW TW112117756A patent/TW202409013A/zh unknown
-
2024
- 2024-06-26 US US18/754,527 patent/US20240368131A1/en active Pending
- 2024-11-12 MX MX2024013978A patent/MX2024013978A/es unknown
- 2024-11-12 JO JOJO/P/2024/0257A patent/JOP20240257A1/ar unknown
- 2024-11-12 CL CL2024003460A patent/CL2024003460A1/es unknown
- 2024-11-12 CO CONC2024/0015371A patent/CO2024015371A2/es unknown
- 2024-11-12 JO JOJO/P/2024/0258A patent/JOP20240258A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024003460A1 (es) | 2025-04-11 |
| MX2024013978A (es) | 2024-12-06 |
| JOP20240258A1 (ar) | 2024-11-12 |
| KR20240172228A (ko) | 2024-12-09 |
| CA3251062A1 (en) | 2023-11-16 |
| CO2024015371A2 (es) | 2024-12-30 |
| IL316674A (en) | 2024-12-01 |
| US20240368131A1 (en) | 2024-11-07 |
| PE20251252A1 (es) | 2025-05-06 |
| EP4522591A1 (en) | 2025-03-19 |
| CN119212978A (zh) | 2024-12-27 |
| WO2023220715A1 (en) | 2023-11-16 |
| AU2023268557A1 (en) | 2024-11-14 |
| JP2025516719A (ja) | 2025-05-30 |
| TW202409013A (zh) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007058A (es) | Derivados de 5,6,7,8-tetrahidro-2,6-naftiridina como terapeuticos contra el cancer. | |
| SA523440916B1 (ar) | Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات | |
| CR20220062A (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| JOP20240258A1 (ar) | مشتقات أوكسو إندولينيل أميد لتثبيط nlrp3 واستخداماتها | |
| JP2022058398A (ja) | Ｂｒａｆ－ｖ６００関連疾患の治療に使用するためのｐｌｘ－８３９４またはｐｌｘ－７９０４ | |
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| PH12022550015A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| NZ766835A (en) | Pharmaceutical compounds | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| PH12020552244A1 (en) | Heterocyclic compounds as trk inhibitors | |
| WO2021232067A8 (en) | Stat3 inhibition for treatment and prevention of human coronavirus infection | |
| CY1124346T1 (el) | ΠΑΡΑΓΩΓΑ ΧΡΩΜΑΝΙΟΥ, ΙΣΟΧΡΩΜΑΝΙΟΥ ΚΑΙ ΔΙΥΔΡΟΪΣΟΒΕΝΖΟΦΟΥΡΑΝΙΟΥ ΩΣ mGluR2-APNHTIKOI ΑΛΛΟΣΤΕΡΙΚΟΙ ΔΙΑΜΟΡΦΩΤΕΣ, ΣΥΝΘΕΣΕΙΣ, ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ | |
| ZA202501471B (en) | Preparation and use of quinazolinone derivative as kinase inhibitor | |
| MX2023003576A (es) | Compuesto como inhibidor de la akt cinasa. | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
| JOP20240217A1 (ar) | مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة | |
| PH12022552727A1 (en) | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| JOP20250076A1 (ar) | طرق لعلاج السرطان باستخدام مشتقات أيزو كوينولين أو 6-آزا-كوينولين | |
| JOP20250232A1 (ar) | مشتقات أميد لتثبيط nlrp3 واستخداماتها | |
| MX2025007158A (es) | Inhibidores de gmp?amp sintasa ciclica y sus usos | |
| MX2022009898A (es) | Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo. |